These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 19173823

  • 1. [Inhibitory effects of a combination of rmhTRAIL and gemcitabine on human non-small cell lung cancer cell line NCI-H460 cells in vitro and in vivo].
    Tang CH, Liu XQ, Yang SF, Zhu B, Gao HJ.
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):808-12. PubMed ID: 19173823
    [Abstract] [Full Text] [Related]

  • 2. [Therapeutic effects of recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand on non-small lung cell cancer: an experimental with rats].
    Tang YM, Yang SF, Zhu B, Cui JS.
    Zhonghua Yi Xue Za Zhi; 2005 Aug 03; 85(29):2021-5. PubMed ID: 16313792
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer.
    Zhang R, Ru Y, Gao Y, Li J, Mao S.
    Drug Des Devel Ther; 2017 Aug 03; 11():2631-2642. PubMed ID: 28919713
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Gemcitabine synergizes with cisplatin to inhibit nasopharyngeal carcinoma cell proliferation and tumor growth.
    He SW, Zhang Y, Chen L, Luo WJ, Li XM, Chen Y, Huang SY, He QM, Yang XJ, Li YQ, Liu N, Zhao Y, Ma J.
    FASEB J; 2021 Oct 03; 35(10):e21885. PubMed ID: 34478585
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer.
    Bajetta E, Stani SC, De Candis D, Zaffaroni N, Zilembo N, Cortinovis D, Aglione S, Mariani L, Formisano B, Bidoli P.
    Ann Oncol; 2003 Feb 03; 14(2):242-7. PubMed ID: 12562651
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Inhibitory effect of bcl-2 antisense oligodeoxynucleotides on growth of human lung carcinoma xenograft in nude mice].
    He DM, Zhang H.
    Ai Zheng; 2006 Jan 03; 25(1):40-4. PubMed ID: 16405747
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M, Benzo A, Irrissuto C, Lopez G, Curatella B, Maggi CA, Manzini S, Crea A, Caroli S, Cubadda F, Binaschi M.
    Cancer Chemother Pharmacol; 2008 Sep 03; 62(4):621-9. PubMed ID: 18038274
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer.
    Hatami E, Nagesh PKB, Jaggi M, Chauhan SC, Yallapu MM.
    Eur J Pharmacol; 2020 Dec 05; 888():173486. PubMed ID: 32805254
    [Abstract] [Full Text] [Related]

  • 18. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
    Fang F, Wang AP, Yang SF.
    Acta Pharmacol Sin; 2005 Nov 05; 26(11):1373-81. PubMed ID: 16225761
    [Abstract] [Full Text] [Related]

  • 19. Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine.
    Vansteenkiste JF, Vandebroek JE, Nackaerts KL, Weynants P, Valcke YJ, Verresen DA, Devogelaere RC, Marien SA, Humblet YP, Dams NL, Leuven Lung Cancer Group.
    Ann Oncol; 2001 Sep 05; 12(9):1221-30. PubMed ID: 11697832
    [Abstract] [Full Text] [Related]

  • 20. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
    Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón M, Sánchez JJ, Danenberg KD, Danenberg PV, Rosell R.
    Clin Cancer Res; 2002 Jul 05; 8(7):2286-91. PubMed ID: 12114432
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.